MARATTO

article · Zoonoses

Hematologic Disorders in Ebola-Infected Patients During the Tenth Outbreak in Butembo, Democratic Republic of Congo: Hemogram Analysis of Ebola Virus Disease Patients During the Outbreak in Butembo 2019–2020

2025Open access

Abstract

Background: Hematologic disorders occur frequently in patients with Ebola virus disease (EVD) and are characterized by one or several abnormalities in blood cells, including hemostasis, which is poorly documented. This study described the hematologic abnormalities of Ebola patients and the impact on the outcomes of patients who were admitted with EVD. Methods: This was a retrospective observational study of patients recruited from 1 February 2019 to 25 June 2020 from Ebola Treatment Centers in Butembo and Katwa. Clinical and hemogram parameters at the time of admission and outcomes were collected. Descriptive statistics and logistic regression were performed with a significance level of 0.05. The analyses were carried out using Rstudio software. Results: Among 299 patients hospitalized during the study period, only 129 were included in the analysis. The mean age was 29.9 ± 18.6 years with a female-to-male ratio of 1.2. Only 13 patients (10 %) had been vaccinated against the Ebolazaire virus. The hematologic abnormalities included anemia (55.8%), hyperleukocytosis (36.4%), leukopenia (3.1%), thrombopenia (32.6%), and thrombocytosis (30.2%). Only anemia was statistically significantly correlated with increased viral load. Anemia (OR, 4.07; 95% CI, 1.59–11.3) was shown to be an independent risk factor for mortality in patients with EVD based on multivariate analysis. Conclusions: EVD is responsible for major hematologic abnormalities that contribute to increased patient mortality.

Research topics

  • Viral Infections and Outbreaks Research
  • Disaster Response and Management
  • Viral Infections and Vectors

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.15212/zoonoses-2024-0042

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.